Clin2
NCT07417566Likely a fitRecruiting

DC6001 Tablet Study in Healthy Chinese Adults

Stargardt Disease

Part of Eyes & vision, Genetic & congenital clinical trials.

This trial tests a new tablet called DC6001 in healthy volunteers. It helps find out how the body processes the drug and if it is safe. You may join if you are a healthy adult between 18 and 55 years old.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
76 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You must be 18 to 55 years old, healthy, and willing to use birth control.
  • Men must weigh at least 110 pounds (50 kg), and women at least 99 pounds (45 kg).
  • Your body mass index (BMI) must be between 19 and 28.
  • You must not smoke more than 5 cigarettes a day on average, and cannot smoke during the study.
  • You must not have taken any other experimental drugs in the last 3 months.
  • You must not have donated blood (400 mL or more) in the last 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07419334Recruiting· Phase 3
Study of a new drug for Stargardt disease

This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.

Phoenix, Arizona
NCT06942572Recruiting· Phase 1/Phase 2
Gene therapy trial for Stargardt disease

This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.

Aurora, Colorado
NCT06435000Recruiting
A study tracking Stargardt disease progression

This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.

San Diego, California
NCT02402660Enrolling by invitation· Phase 2
Test ALK-001 for Stargardt disease eye changes and comfort

This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.

Phoenix, Arizona
NCT07439887Recruiting· Phase 1/Phase 2
Study of an injection for Stargardt disease

This trial tests a single injection of a new medicine, RTx-021, into the eye for people with Stargardt disease. The goal is to see if it is safe and to find the right dose.

Bakersfield, California
NCT07521345Recruiting· Phase 1
Safety Study of HSK55879 Tablet in Healthy Adults

This early-stage study tests how a new experimental medication (HSK55879) is tolerated and processed by the body in healthy volunteers. Researchers will also check how food affects the drug's absorption to help determine safe dosing for future patient studies.

Hefei, Anhui

Hear when a new Stargardt Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.